Soleno Therapeutics, Inc. - Common Stock (SLNO)

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive agreement to acquire Celeno Therapeutics (NASDAQ: SLNO). The all-cash transaction, valued at approximately $2.9 billion, underscores a strategic push

The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most significant mid-cap success stories of the decade. Soleno Therapeutics (NASDAQ: SLNO) has transitioned from a struggling diagnostics firm to a commercial powerhouse, culminating in [...]

Neurocrine’s rare-disease push, anchored by Soleno’s VYKAT XR, reshapes biotech dealmaking focus, today, April 6, 2026.

It's being acquired by a peer.

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium

Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other gainers include Xiao-I Corp (NASDAQ: AIXI), Profusa Inc (NASDAQ: PFSA), and Soleno Therapeutics Inc (NASDAQ: SLNO). Losers include Intercont (Cayman) Ltd (NASDAQ: NCT), Visionary Holdings Inc (NASDAQ: GV), and PMGC Holdings Inc (NASDAQ: ELAB).

This technology firm provides cloud-based compliance and reporting solutions for organizations with complex regulatory needs worldwide.

The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.

Soleno (SLNO) Q4 2025 Earnings Call Transcript

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three quarters of the year, the rare-disease specialist has encountered a late-year slump, retreating from its 52-week

Soleno just turned profitable for the first time—right as a major fund made its move.

Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.